Albumin    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2
20Adrenoleukodystrophy2
51Scleroderma1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02479802
(ClinicalTrials.gov)
November 201410/6/2015Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral SclerosisPilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: AlbuminInstituto Grifols, S.A.NULLCompleted18 Years70 YearsAll13Phase 2Spain
2EUCTR2013-004842-40-ES
(EUCTR)
09/05/201407/03/2014Pilot study to evaluate the effect of plasma exchange with albumin in patients with amyotrophic lateral sclerosisPilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis - Albumin in ALS Amytrophic Lateral Sclerosis (ALS)
MedDRA version: 16.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Albutein 5%
INN or Proposed INN: albúmina humana
Other descriptive name: HUMAN ALBUMIN SOLUTION
Instituto Grifols S.A.NULLNot RecruitingFemale: yes
Male: yes
Phase 4Spain

20. Adrenoleukodystrophy    [ 49 clinical trials,   86 drugs,   (DrugBank: 29 drugs),   18 drug target genes,   112 drug target pathways]
Searched query = "Adrenoleukodystrophy", "Adrenomyeloneuropathy", "AMN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 49 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04303416
(ClinicalTrials.gov)
March 9, 20206/3/2020Plasma Exchange With Albumin in AMN PatientsEffect of Plasma Exchange With Albumin in Patients With Adrenomyeloneuropathy: Unicentric, Single Arm, Proof of Concept Study.Adrenomyeloneuropathy;AdrenoleukodystrophyDrug: Albumin solutionOnofre, Aurora Pujol, M.D.NULLNot yet recruiting18 Years65 YearsMale5Phase 2;Phase 3Spain
2EUCTR2019-004733-17-ES
(EUCTR)
25/02/202020/12/2019Plasma exchange by albumin replacement in AdrenomyeloneuropathyEffect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial Adrenomyeloneuropathy
MedDRA version: 20.0;Level: LLT;Classification code 10069075;Term: Adrenomyeloneuropathy without cerebral involvement;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Aurora Pujol OnofreNULLAuthorised-recruitment may be ongoing or finished Female: no
Male: yes
5Phase 2Spain

51. Scleroderma    [ 466 clinical trials,   536 drugs,   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways]
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 466 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00769028
(ClinicalTrials.gov)
December 20087/10/2008AIMSPRO in Established Diffuse Cutaneous Systemic SclerosisA Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic SclerosisSystemic SclerosisDrug: Hyperimmune caprine serum;Drug: AlbuminDaval International LimitedNULLActive, not recruiting18 YearsN/ABoth20Phase 2United Kingdom